Daewoong Pharmaceutical Co., Ltd (KRX: 069620)

Market Cap	1.61T
Revenue (ttm)	1.42T
Net Income (ttm)	103.57B
Shares Out	11.51M
EPS (ttm)	9,001.68
PE Ratio	15.55
Forward PE	15.95
Dividend	600.00 (0.43%)
Ex-Dividend Date	Dec 27, 2024

Volume	33,760
Average Volume	35,432
Open	133,000
Previous Close	131,800
Day's Range	132,400 - 140,000
52-Week Range	100,100 - 164,400
Beta	0.83
RSI	57.85
Earnings Date	Feb 10, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,727
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2023, Daewoong Pharmaceutical's revenue was 1.38 trillion, an increase of 7.44% compared to the previous year's 1.28 trillion. Earnings were 121.74 billion, an increase of 188.21%.